ABSTRACT
INTRODUCTION: Increasing numbers of metastatic melanoma (MM) patients are receiving immunotherapy treatment, including pembrolizumab, and the impact on their well-being is underexplored. OBJECTIVES: To assess the feasibility of a multimodal supportive care program to MM patients being treated with pembrolizumab. METHODS: This pre-post-test feasibility cohort study recruited MM participants treated with pembrolizumab: (i) supportive care intervention with usual care and (ii) usual care. The intervention comprised comprehensive medical assessment by supportive care physician (SCP), exercise physiologist (EP), and dietitian then a tailored supportive care program. Programs included exercise, dietary advice, non-invasive complementary therapies, and psychology consultation. Outcome measures included adherence, patient-reported symptoms, anxiety and depression, and toxicity. Descriptive data are reported. RESULTS: We recruited 28 participants: 13 intervention and 15 control; three did not complete the study. Most were male, with median age 66 (range 42-85) years. All intervention participants completed baseline assessments with SCP, EP, and dietitian. Two missed follow-up with EP or dietitian. Symptoms most troubling at baseline were as follows: fatigue (n = 6), sleep (n = 6), general aches and pains (n = 5), and memory (n = 4). All intervention participants were prescribed 16 exercise sessions; 8 (50%) completed all; overall exercise adherence was 85%. Integrative therapies were accessed by 85% (11) participants. Immunotherapy-related adverse event rates were low and SCP consultation identified symptoms not captured by CTCAE 4.0. CONCLUSIONS: A holistic supportive care intervention tailored to individual needs is feasible. The symptom burden in MM patients was low. Further investigation of the intervention is warranted, focused on populations with higher symptom burden to improve outcomes.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Melanoma/therapy , Palliative Care/methods , Patient Acceptance of Health Care , Perception , Adult , Aged , Aged, 80 and over , Cohort Studies , Combined Modality Therapy/methods , Diet Therapy , Exercise Therapy , Feasibility Studies , Female , Humans , Immunotherapy/methods , Male , Melanoma/pathology , Melanoma/psychology , Middle Aged , Musculoskeletal Manipulations , Neoplasm Metastasis , Patient Acceptance of Health Care/statistics & numerical data , Pilot Projects , Quality of Life , Risk AssessmentABSTRACT
We report a case of isolated immune-related pancreatic exocrine insufficiency in a patient treated with pembrolizumab for metastatic melanoma. This patient presented with explosive diarrhea and was treated with high dose corticosteroids for possible immune-related colitis. However, biopsies from colon and duodenum did not show any histological evidence of colitis/enteritis. Serum amylase and lipase were not elevated. There was no evidence of pancreatitis or pancreatic metastases on imaging. Significantly lower fecal elastase test on two occasions confirmed the diagnosis of pancreatic exocrine insufficiency. He was treated with pancreatic enzyme supplementation with complete resolution of diarrhea. This case reinforces the importance of awareness and anticipation of unusual immune-related adverse events related to checkpoint inhibitors.
Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Exocrine Pancreatic Insufficiency/chemically induced , Immunotherapy/adverse effects , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Exocrine Pancreatic Insufficiency/diagnosis , Exocrine Pancreatic Insufficiency/drug therapy , Feces/enzymology , Gastrointestinal Agents/therapeutic use , Humans , Male , Melanoma/secondary , Melanoma/therapy , Pancreatic Elastase/analysis , Pancrelipase/therapeutic use , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Treatment OutcomeABSTRACT
BACKGROUND: Targeted therapy and immunotherapy agents for advanced melanoma are associated with novel toxicities. Melanoma clinical nurse consultants (CNCs) provide multifaceted clinical care.â©. OBJECTIVES: The objective was to evaluate the type of support, excluding clinic and inpatient care, provided by CNCs for patients not enrolled in a clinical trial.â©. METHODS: A prospective review of CNC support provided during a 12-week period was conducted.â©. FINDINGS: From May to August 2015, 105 patients attended clinic, and 72 received CNC support. Initial patient encounters with CNCs were documented (n = 150), as well as additional interactions (n = 291). The most common problem identified per initial encounter was symptom/drug toxicity. The most common therapy-related concern was related to anti-programmed cell death protein 1 immunotherapy and BRAF plus MEK inhibition. CNC interventions commonly involved clinical advice and counseling and care coordination.
